Sanofi and Synthekine will work together to develop cytokine therapies for inflammatory diseases. This new alliance comes as Sanofi is salvaging a different cytokine therapy that showed disappointing efficacy in Phase 2 after the pharma giant acquired it in a $2.5 billion deal.
Sanofi did not see the efficacy it wanted in mid-stage tests of a cytokine therapy from its $2.5 billion acquisition of Synthorx. While the pharmaceutical giant isn’t giving up on the drug, it said it will restart the molecule in a new Phase 1/2 program, a setback that will lead to a €1.6 billion financial writedown.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Roche announced it will acquire Good Therapeutics, a Seattle-based preclinical biotech, for $250 million. The deal makes Roche responsible for developing and commercializing Good's lead program, which seeks to make oncology drugs that target PD-1 proteins more effective, such as Keytruda or Opdivo.
Jazz Pharmaceuticals is licensing rights to a Werewolf Therapeutics cytokine therapy that’s on track to reach clinical testing next year. The deal gives Jazz a drug candidate that expands the company’s scope to immuno-oncology.
The field of biotechs pursuing new interleukin-2 cancer immunotherapies is filled with companies engineering different versions of that signaling protein. Avenge Bio CEO Mike Heffernan said his startup stands apart with a cell therapy that produces human IL-2 that could offer advantages compared to engineered versions of that protein.
Armo Biosciences secured an impressive Series C round to advance its lead immunotherapy product into phase 2/3 trials.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
The ability to fight off infections could actually be improved by looking at people who are sick.